Clinical Trials
Prognostic Impact of Mismatch Repair Deficiency in Oesophagogastric Adenocarcinoma
Ntellas et alBritish Journal of Cancer

An analysis of 1,424 patients with resectable oesophagogastric adenocarcinoma enrolled in the prospective MRC OE05 and ST03 clinical trials evaluated the prognostic impact of DNA mismatch repair (MMR) status in the setting of perioperative cytotoxic chemotherapy. Mismatch repair deficiency (MMRd) was identified in 5.5% (n = 78) of tumors, with MLH1 loss accounting for 80.8% of MMRd cases.
Univariable analysis demonstrated that patients with MMRd tumors achieved significantly improved overall survival (OS) compared to those with MMR proficient (MMRp) disease, with median OS unreached versus 28.0 months (p = 0.0009) and 5-year OS rates of 50.1% versus 34.3%, respectively. Progression-free survival (PFS) was similarly superior in the MMRd cohort, with a median PFS of 56.7 months compared with 21.4 months in the MMRp cohort (p = 0.0032). In multivariable analysis adjusting for clinicopathological variables, MMRd remained an independent favorable prognostic marker for both OS (HR 0.60, 95% CI 0.42–0.87; p = 0.007) and PFS (HR 0.64, 95% CI 0.45–0.90; p = 0.011). Post-progression survival (PPS) did not differ significantly according to MMR status.
These findings suggest that receiving perioperative cytotoxic chemotherapy does not negate the favorable prognostic effect of MMR deficiency prior to disease progression. The study provides evidence challenging clinical concerns that perioperative cytotoxic regimens may exert a negative effect on outcomes in patients with resectable MMRd oesophagogastric adenocarcinoma.
Key Takeaways
- In patients with resectable oesophagogastric adenocarcinoma receiving perioperative chemotherapy, mismatch repair deficiency (MMRd) was independently associated with significantly superior overall survival compared to MMR proficiency (multivariable HR 0.60, 95% CI 0.42–0.87, p = 0.007; median OS unreached vs 28.0 months; 5-year OS 50.1% vs 34.3%).
- MMRd status predicted significantly prolonged progression-free survival compared to MMR proficiency (multivariable HR 0.64, 95% CI 0.45–0.90, p = 0.011; median PFS 56.7 vs 21.4 months), though post-progression survival did not significantly differ by MMR status.
- These findings challenge existing clinical concerns that perioperative cytotoxic chemotherapy may be detrimental in resectable MMRd oesophagogastric adenocarcinoma, demonstrating that chemotherapy does not eliminate the favorable pre-progression prognostic impact of MMR deficiency.
Read the original sourceBritish Journal of Cancer
